Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$41.71 USD

41.71
3,332,734

+0.28 (0.68%)

Updated Aug 23, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (90 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Sarepta (SRPT) Seeks Label Expansion for DMD Gene Therapy

by Zacks Equity Research

Sarepta (SRPT) files a supplement with the FDA seeking to expand its recently-approved gene therapy Elevidys' label to treat all DMD patients, regardless of age and ambulatory status.

Roche's (RHHBY) sBLA for Xolair Gets FDA Priority Review Tag

by Zacks Equity Research

The FDA accepts and grants priority review to Roche's (RHHBY) supplemental biologics license application for Xolair for the reduction of food allergic reactions. A decision is due in the first quarter of 2024.

LLY Down as Patients Regain Weight After Stopping Zepbound

by Zacks Equity Research

Full results from a late-stage study show that patients who stopped taking Eli Lilly's (LLY) weight-loss drug for over a year slowly started to regain their lost weight.

Regeneron (REGN) Posts Positive Data on Blood Cancer Candidate

by Zacks Equity Research

Regeneron's (REGN) multiple myeloma candidate demonstrates strong rates and depth of response in pre-treated patients.

Solid Biosciences' (SLDB) DMD Drug Gets Fast Track Tag, Stock Up

by Zacks Equity Research

Solid Biosciences (SLDB) gains 68% as the FDA grants Fast Track designation to the company's gene therapy candidate, SGT-003, for the treatment of Duchenne muscular dystrophy.

The Zacks Analyst Blog Highlights Alphabet, NVIDIA, Roche, Intuit and AT&T

by Zacks Equity Research

Alphabet, NVIDIA, Roche, Intuit and AT&T are included in this Analyst Blog.

Sheraz Mian headshot

Top Research Reports for Alphabet, NVIDIA & Roche

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), NVIDIA Corporation (NVDA) and Roche Holding AG (RHHBY).

Roche (RHHBY) Breast Cancer Drug Meets Primary Goal in Phase III

by Zacks Equity Research

Roche's (RHHBY) phase III study evaluating inavolisib in combination with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation achieves its primary goal.

Mark Vickery headshot

Small-Cap Russell Leads the Way, Jobs Data to Come

by Mark Vickery

Only the small-cap Russell 2000 managed to stay above zero the entire trading day.

Roche (RHHBY) to Acquire Obesity Drug Maker Carmot for $2.7B

by Zacks Equity Research

Roche (RHHBY) aims to enter the promising and much-in-demand obesity drug market with the acquisition of Carmot Therapeutics, Inc. for $2.7 billion.

Novartis (NVS) Raises Mid-Term Sales Outlook; Outlines Strategy

by Zacks Equity Research

Novartis (NVS) increases its sales guidance for the mid-term (2022-2027) and outlines its growth strategy as a pure-play pharmaceutical company.

Regeneron (REGN), Sanofi's Dupixent Succeeds in 2nd COPD Study

by Zacks Equity Research

Regeneron (REGN) and partner Sanofi (SNY) post positive data from the second COPD study and plan to submit a sBLA to the FDA by the end of 2023.

Regeneron (REGN) Stock Rallies 10% YTD: What Lies Ahead?

by Zacks Equity Research

Regeneron (REGN) shares gain 10% year to date on Eylea HD's approval and Dupixent's momentum. Pipeline progress is impressive as well.

Here's Why You May Invest in Puma Biotechnology (PBYI) Stock

by Zacks Equity Research

Here, we discuss some reasons why investing in Puma Biotechnology (PBYI) stock now may turn out to be a more prudent move than ever.

Prothena (PRTA) Pipeline Shows Promise in a Tough AD Market

by Zacks Equity Research

Prothena (PRTA) makes good progress with its AD candidates. However, AD is a challenging space and the successful development of these candidates is crucial.

Solid Biosciences (SLDB) Stock Up as FDA Clears DMD Drug IND

by Zacks Equity Research

Solid Biosciences (SLDB) gains 28% as the FDA clears SGT-003, a gene therapy candidate, for clinical studies in the treatment of Duchenne Muscular Dystrophy.

Roche (RHHBY) Tecentriq SC Receives Positive CHMP Opinion

by Zacks Equity Research

Roche's (RHHBY) subcutaneous (SC) formulation of immuno-oncology drug Tecentriq gets CHMP's positive recommendation for all approved indications.

Biogen (BIIB) Beats on Q3 Earnings & Sales, Cuts EPS View

by Zacks Equity Research

Biogen (BIIB) beats third-quarter estimates for earnings and sales. It lowers its 2023 EPS guidance range to include the impact of dilution from the Reata acquisition. Stock rises in pre-market.

Halozyme (HALO) Q3 Earnings Top Estimates, Revenues Lag

by Zacks Equity Research

Halozyme's (HALO) third-quarter earnings beat estimates, while revenues miss the same. The company maintains revenue guidance for full-year 2023.

Biogen (BIIB) to Report Q3 Earnings: Will It Beat Estimates?

by Zacks Equity Research

Biogen's (BIIB) sales in the third quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have improved.

Alnylam (ALNY) Swings to Earnings in Q3 on Collaboration Revenues

by Zacks Equity Research

Alnylam (ALNY) reports better-than-expected third-quarter 2023 results, beating both earnings and sales estimates on the back of higher collaboration revenues.

Prothena (PRTA) Q3 Earnings Beat on Collaboration Revenue Hike

by Zacks Equity Research

Prothena (PRTA) delivers earnings of 38 cents in the third quarter, driven by the license and option exercise fee paid by BMY.

Regeneron (REGN) Q3 Earnings & Sales Top, Eylea Sales Decline

by Zacks Equity Research

Regeneron (REGN) beats earnings and sales estimates in third-quarter 2023, fueled by Dupixent. However, sales of the lead drug, Eylea, fall yet again.

Sarepta (SRPT) Q3 Loss Narrower Than Expected, Sales Beat

by Zacks Equity Research

Sarepta's (SRPT) Q3 earnings and sales beat estimates on the back of strong sales for recently approved DMD gene therapy Elevidys.

Blueprint (BPMC) Stock Gains 26% on Q3 Earnings & Sales Beat

by Zacks Equity Research

Blueprint (BPMC) climbs 26% on better-than-expected third-quarter 2023 results, driven by increased Ayvakit sales following the drug's label expansion in the United States.